Skip to nav Skip to content

Clinical Management and Prevention of Clade II Mpox: Plus, HPAI Update - Jointly hosted with HIVMA

Facebook Twitter LinkedIn Email

To Download a copy of the presentation click here.
To Download a copy of the updated Q&A Responses click here.

Dana S. Wollins, DrPH, MGC
Senior Vice President, Strategy
Infectious Diseases Society of America


HPAI Update
Jay Butler, MD, FIDSA
Deputy Director for Infectious Diseases
U.S. Centers for Disease Control and Prevention

Epidemiology of Clade II Mpox
Agam Rao, MD, FIDSA
CAPT, U.S. Public Health Service
Medical Officer
Poxvirus and Rabies Branch
U.S. Centers for Disease Control and Prevention

Update on Mpox Vaccinations
Meghan Pennini, PhD
Chief Vaccines and Therapeutics Officer
HHS Coordination Operations and Response Element (H-CORE)
Administration for Strategic Preparedness and Response
U.S. Department of Health and Human Services

Update on Tecovirimat EA-IND Eligibility Criteria for Treatment for Mpox
Patty Yu, MPH
Regulatory Health Scientist
U.S. Centers for Disease Control and Prevention

Q&A and Discussion — All Presenters Plus:
Robert Goldstein, MD, PhD
Massachusetts Department of Public Health

Boghuma K. Titanji, MD, MSc, DTM&H, PhD
Assistant Professor of Medicine
Emory University School of Medicine

Timothy Wilkin, MD
Assistant Dean for Clinical Research Compliance
Weill Cornell Medical College

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.